Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
KING OF PRUSSIA, Pa., March 02, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 8, 2017 at 8:00 am EST to review financial results as of and for the year ended December 31, 2016 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 81728820).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 81728820). Following the conclusion of the call, the webcast will be available for replay for 30 days.
Separately, the Company will be webcasting its corporate presentation at the Cowen 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. EST in Boston. This presentation will include discussion of how recently-reported data support the Company’s plans for regulatory approval and subsequent commercialization of OLINVO™ (oliceridine injection) in the U.S.
To join a live audio webcast of the Cowen presentation, please visit the Investor Presentation section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734 for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
